Abstract
Maternal and Neonatal Outcomes After Monoclonal Antibody Use [ID: 1376620]
Obstetrics and gynecology (New York. 1953), Vol.141(5S), pp.75S-75S
05/2023
DOI: 10.1097/01.AOG.0000930888.41961.e2
Abstract
INTRODUCTION:The study aimed to evaluate whether the administration of monoclonal antibodies (MABs) in mildly symptomatic unvaccinated COVID-19-positive pregnant patients reduced the need for maternal hospitalization and to evaluate whether this medication affected the rate of adverse neonatal outcomes and severe maternal disease. We hypothesized that MAB use would reduce the need for hospitalization.METHODS:This retrospective cohort study was completed by obtaining electronic medical record data of all pregnant patients between August 2020 and January 2022 who met criteria for MAB therapy. The two comparison groups were patients who received outpatient MAB therapy during pregnancy and those who were eligible for therapy but declined. Demographic and hospitalization data were obtained. Exclusion criteria included severe illness upon diagnosis requiring hospitalization, or patients for whom delivery and neonatal data were not available.RESULTS:During the study period, 49 patients qualified for MAB therapy, of which delivery data were available for 39 patients. Twenty patients (51%) elected to receive MAB therapy and 19 (49%) declined. Among those who received MAB therapy, 10 (26% of the population) were vaccinated, and among those who declined, 6 (15% of the population) were vaccinated. The two groups were similar in gestational age at delivery (38 weeks 4 days versus 37 weeks 5 days) and gestational age at diagnosis (19 weeks 0 days versus 22 weeks 6 days). Among patients who did not receive MABs, both absolute and relative maternal hospitalization rate was higher (26.3% versus 5%, 12.8% versus 3%, P>.05). When stratified by vaccination status, those who were vaccinated had a 5% probability of hospitalization regardless of MAB therapy. The probability of hospitalization was highest among unvaccinated women who did not receive MAB therapy (67%) and lowest among unvaccinated women who received MAB therapy (0%).CONCLUSION:Unvaccinated patients who declined MAB therapy had a higher rate of hospitalization, although not statistically significant. These preliminary findings warrant further study with a larger cohort.
Details
- Title: Subtitle
- Maternal and Neonatal Outcomes After Monoclonal Antibody Use [ID: 1376620]
- Creators
- Andrew Storm - University of Iowa Hospitals and Clinics, Iowa City, IAAnnemarie Gilley - University of Iowa Hospitals and Clinics, Iowa City, IAAndrea Greiner - University of Iowa
- Resource Type
- Abstract
- Publication Details
- Obstetrics and gynecology (New York. 1953), Vol.141(5S), pp.75S-75S
- Publisher
- Lippincott Williams & Wilkins
- DOI
- 10.1097/01.AOG.0000930888.41961.e2
- ISSN
- 0029-7844
- Language
- English
- Date published
- 05/2023
- Academic Unit
- Obstetrics and Gynecology
- Record Identifier
- 9984810939202771
Metrics
1 Record Views